Sarcoma of PelvisPhase 2NCT00181025
Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle
A Phase 2 study testing Tasonermine (TNFa) and Melphalan in people with Sarcoma of Pelvis, run by Gustave Roussy, Cancer Campus, Grand Paris at 1 site in France.
Trial summary
This study looks at isolated pelvic perfusion and limbs' girdle with 1 mg tumor necrosis factor alpha (TNFa) in the treatment of locally advanced sarcoma of the pelvis and limbs' girdle. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Sarcoma of Pelvis
- What is being tested?
- Tasonermine (TNFa) and Melphalan
- How many people
- 33 participants
- Where
- 1 siteFrance
- Study dates
- May 2004to not given
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Soft tissue or bone sarcomas locally advanced of the pelvis or limbs' girdle
Who cannot join
- Resectable tumor without mutilation
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Institut Gustave-Roussy
Villejuif, 94800
Sylvie Bonvalot, MD, 33 1 42 11 35 63, bonvalot@igr.fr
About this study
Official title: Isolated Pelvic and Limb Perfusion With 1mg TNFa in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle
This study looks at isolated pelvic perfusion and limbs' girdle with 1 mg tumor necrosis factor alpha (TNFa) in the treatment of locally advanced sarcoma of the pelvis and limbs' girdle.
- Conditions
- Sarcoma of Pelvis
- Being tested
- Tasonermine (TNFa), Melphalan
- Keywords
- Limbs' girdle
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tasonermine (TNFa)Drug
MelphalanDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete response rate on MRI
Secondary outcomes (5)
Histological response
Objective responses
Rate of conservative treatments
Overall survival and disease free survival
Local and systemic toxicity
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2005 (estimated)
- Study startMay 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sarcoma of PelvisStudies of the same condition, open and under way.
- More trials run by Gustave Roussy, Cancer Campus, Grand ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 33 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Sponsor type
- University, hospital or other
- Investigators
- Sylvie Bonvalot, MD, Principal investigator, Gustave Roussy, Cancer Campus, Grand Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00181025
- Sponsor's protocol ID
- PIP
- Other IDs
- CSET 2003/1053
- Status last verified
- Sep 2006
- First submitted
- 13 Sep 2005
- Last updated
- 12 Jun 2007
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Isolated Pelvic and Limb Perfusion With 1mg TNFa in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle
- ClinicalTrials.gov ID
- NCT00181025
- Acronym / sponsor ID
- PIP
- Conditions
- Sarcoma of Pelvis
- Keywords
- Limbs' girdle
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 33 participants (estimated)
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisUniversity, hospital or other
- Study start
- May 2004
- First posted
- 16 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study looks at isolated pelvic perfusion and limbs' girdle with 1 mg tumor necrosis factor alpha (TNFa) in the treatment of locally advanced sarcoma of the pelvis and limbs' girdle.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Soft tissue or bone sarcomas locally advanced of the pelvis or limbs' girdle
Key exclusion criteria (1 listed)
- Resectable tumor without mutilation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tasonermine (TNFa) | Drug | – |
| Melphalan | Drug | – |
Primary outcome
Complete response rate on MRI
5 secondary outcomes
Histological response
Objective responses
Rate of conservative treatments
Overall survival and disease free survival
Local and systemic toxicity
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2007.
Related trials for Sarcoma of Pelvis
Active, not recruitingObservational study
Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors
Endometrial Carcinoma, Malignant Uterine Neoplasm
Recruiting
Patient-Specific Computational Walking Models in Improving Surgical and Rehabilitation Treatment in Patients With Pelvic Sarcomas
Pelvic Sarcoma
Active, not recruitingPhase 4
Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®
Sarcoma
RecruitingObservational study
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
Bone Sarcoma, Chondrosarcoma
RecruitingPhase 1/2
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Cancer, Sarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sylvie Bonvalot, MD principal investigator
Gustave Roussy, Cancer Campus, Grand Paris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Tasonermine (TNFa) and Melphalan in people with Sarcoma of Pelvis, run by Gustave Roussy, Cancer Campus, Grand Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Jun 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Sylvie Bonvalot, MD (33 1 42 11 363, bonvalot@igr.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete response rate on MRI. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2007.